Transition Bio
UK-based provider of a microfluidics-driven drug discovery platform using biophysical sciences and artificial intelligence tools to map and modulate biomolecular condensates
Transition Bio has raised €47M across 1 funding round from 5 investors, most recently a Series A round in Jun 2022. Based in Cambridge, UK; active in Healthtech. Data as of 28 Oct 2026.
Cambridge, UKtransitionbio.com ↗
Total raised
€47M
€46,598,322
Funding rounds
1
Investors
5
distinct backers
Active since
2022-06
latest 2022-06
Funding by year
EUR raised per yearTransition Bio — funding by year — interactive chart.
Data table
| Transition Bio — funding by year | |
|---|---|
| 2022 | €47M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-03 | Series A | €47M | Bristol Myers Squibb,Lifeforce Capital,Magnetic Ventures,Northpond Ventures,Taiho Ventures | View deal → |
Related news
- Transition Bio Closes $50M Series A Financingfinsmes.com · 2022-06
Similar companies
same sector or countryGlobal coverage: FundingData